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Background: Investigating the neutralizing antibody (NAb) titer against HSV-1 is essential for monitoring the
immune protection against HSV-1 in susceptible populations, which would facilitate the development of vaccines
against herpes infection and improvement of HSV-1 based oncolytic virotherapy.
Results: In this study, we have developed a neutralization test based on the enzyme-linked immunospot assay
(ELISPOT-NT) to determine the neutralizing antibody titer against HSV-1 in human serum samples. This optimized
assay employed a monoclonal antibody specifically recognizing glycoprotein D to detect the HSV-1 infected cells.
With this test, the neutralizing antibody titer against HSV-1 could be determined within one day by automated
interpretation of the counts of cell spots. We observed good correlation in the results obtained from ELISPOT-NT
and plaque reduction neutralization test (PRNT) by testing 22 human serum samples representing different titers.
Moreover, 269 human serum samples collected from a wide range of age groups were tested, the average
neutralizing antibody titer (log2NT50) was 8.3 ± 2.8 and the prevalence of NAbs was 83.6 % in this cohort, it also
revealed that the average neutralizing antibody titer in different groups increased with the age, and no significant
difference in neutralizing antibody titers was observed between males and females.
Conclusions: These results prove that this novel assay would serve as an accurate and simple assay for the
assessment of the neutralizing antibody titers against HSV-1 in large cohorts.
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Herpes simplex virus type 1 (HSV-1) is the causative
pathogen of orolabial herpes, one of the most prevalent
oral transmitted diseases worldwide. More than 60 % of
people worldwide were infected with HSV-1 during their
lifetime [1, 2]. HSV-1 infection may become chronic,
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of morbidity and mortality in the newborn and immuno-
compromised individuals [3, 4]. Moreover, HSV-1 also
accounts for a substantial proportion of genital herpes in-
fections [5]. HSV-1 viruses cannot be eradicated, which
can establish latency for lifelong in sensory ganglia follow-
ing initial acquisition, thus the majority of people infected
with HSV-1 stay in a state of “asymptomatic”.
Generation of humoral immunity and cellular immun-
ity was indicated to play a crucial role in controlling her-
pes virus shedding [6, 7]. Neutralizing antibodies (NAbs)
to viral glycoproteins were elicited in response to HSV-1
infection [8], which may provide some certain protection
against HSV-1 acquisition or reduce the severity ofdistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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lence against HSV-1 in susceptible populations is essen-
tial for monitoring the seroconversion rates in countries
where HSV-1 is endemic to evaluate the effectiveness of
vaccination and anti-viral therapy against herpes infec-
tion, especially to HSV-2 infection. Moreover,HSV-1
based oncolytic virus, which usually contain attenuated
modifications and expresses multiple therapeutic genes,
had been proved to be good therapeutic gene therapy
vectors for treating central nervous disease and multiple
cancers [11, 12]. NAbs against HSV-1 are one of the bar-
riers oncolytic viruses encounter during viral replication
in vivo. However, it is largely unknown whether the cir-
culating NAbs in cancer patients will restrict the efficacy
of HSV-1 based virotherapy, especially when the viruses
are administrated through intravenous delivery [13].
Thus, it’s intriguing for us to know the average NAb ti-
ters in general population, the relationship between
HSV-1 serostatus and NAb titers, and which amount of
NAbs will affect the efficacy of HSV-2 vaccine, as well as
HSV-1 based oncolytic virotherapy.
Conventional assays previously employed to quantita-
tively determine the NAb titers against herpes virus in-
clude the cytopathic effect-based neutralization test
(CPE-NT) and the plaque reduction neutralization test
(PRNT) [14, 15], which are widely accepted and consid-
ered the laboratory gold standard test. However, these
assays are arduous and time consuming, requiring long
time of infections and plenty of manual counting jobs.
Thus, these tests may not be feasible to screen large co-
horts from clinical trials or epidemiology studies. There-
fore, a high-throughput assay is needed for rapid and
precise evaluation of the NAb titers against HSV-1.
Then ELISPOT is a powerful tool for detection and
quantification of single secreting cell in a 96 well plate.
The ELISPOT with high sensitivity has been successfully
applied to detect low frequency cells secreting cytokines,
antigens and antibodies, which is widely used in im-
munological studies and vaccine development [16–18].
Recently, the ELISPOT assay has been adapted to meas-
ure the NAb titers against various viruses, such as HIV,
enterovirus and dengue virus [19–21]. In this study, we
established a high-throughput, quantitative and reliable
ELISPOT-based neutralization test (ELISPOT-NT) to
rapidly measure the neutralizing antibody titer against
HSV-1 in human serum samples. Employing this test,
we depicted the prevalence of NAbs among a cohort
with wide range of ages.
Results
Characterization of the MAbs in this study
To develop MAbs with high reactivity toward HSV-1
virus, we selected 12 MAbs from more than 60 MAbs
that were developed in our laboratory, which canspecifically bind to HSV-1 infected cells by ELISPOT
assay. Among these 12 MAbs, 2G5 MAb showed with
highest sensitivity against HSV-1 compared with other
antibodies when tested at the same antibody concentra-
tion (Fig. 1a), so 2G5 MAb was selected as the detection
antibody. It was observed that 2G5 specifically reacted
with HSV-1 infected cells rather than control cells, and
legible spots could be formed for subsequent analysis
(Fig. 1b). It was found that 2G5 harbored good re-
activity with other HSV-1 strains, such as strain F
and strain 17, and cross-reacted weakly with HSV-2
(Fig. 1c). 12 viral glycoproteins (gB ~ gN) were
employed to determine the target protein of 2G5
MAb, it revealed that 2G5 MAb specifically recog-
nized denature or naïve form of glycoprotein D (gD)
without any background (Fig. 1d and e).
Influence of infection parameters on the detection of cells
infected with HSV-1
The ELISPOT neutralizing test was based on the use of
2G5 to detect the cells infected with HSV-1, thus the
optimization of experimental parameters, such as infec-
tion time, antibody concentration and infectious dose,
was a crucial step in the establishment of 2G5 based
ELISPOT assay. First, we depicted the infection kinetics
of HSV-1 in U-2 OS cells in order to determine the opti-
mized infection time, when we can precisely quantify in-
dividual spots. U-2 OS cells were infected with KOS at a
MOI of 0.005, then the number of spots was counted
every 6 h for a total of 108 h. As shown in Fig. 2a, the
growth curve of HSV-1 was divided into four phases:
Lag phase (0–12 h), Log phase (12–72 h), Stationary
phase (72–90 h) and Death phase (90–108 h). It was
speculated that the virus might go through an entire
life cycle within 12 h post infection. The expression
of gD protein usually occurred in the mid/late stage
of viral infection, so the infection time for detection
was set as 14 h. Next, 2G5 MAb (1.6 mg/mL) was
firstly started with a 50-fold dilution, then 2-fold ser-
ial dilutions of 2G5 MAb were tested by their re-
activity with HSV-1 infected cells, the maximum
number of spots were not affected when antibody
concentration ranged from 8 μg/mL to 32 μg/mL
were used in the detection (Fig. 2b). Thus the work-
ing concentration of 2G5 MAb was set as 8 μg/mL.
Moreover, we investigated the role of infectious dose
on the detection of HSV-1 infection. Interestingly, it
was observed that the spot count was indeed lower
than the number of input viruses. Infection with high
MOI and infectious deficiency may account for this
phenomenon. However, a good correlation between
infectious doses and spot counts (R2 = 0.9814) was
observed in Fig. 3c, the linear range of the infectious





Fig. 1 Specificity of MAbs in detecting the HSV-1 infected cells. a 12 MAbs were selected from a panel of 60 antibodies developed in our laboratory
for specifically recognizing the HSV-1 infected cells. The Cell based ELISPOT assay was used in the detection. b Schematic image of the 2G5 antibody
in detecting the HSV-1 (KOS strain) infected cells and mock-infected cells, the shown blue spots indicate the viral infection. c The reactivity of 2G5
against other HSV viruses. U-2 OS cells were infected with HSV-2 (Strain 186), HSV-1 (Strain 16, Strain F, Strain KOS), cells were harvested 48 h after
transfection and total protein was extracted and analyzed by Western Blot. d The reactivity of 2G5 against HSV-1 glycoproteins. U-2 OS cells were
transfected with 12 glycoprotein constructs (plv-gB ~ gN). Cells were harvested 48 h after transfection and total protein was extracted and analyzed by
Western Blot. KOS infected cell lysate was taken as a control. e Immunofluorescence analysis of the specificity of 2G5 MAb. After plv-gD transfection
and puromycin selection, gD expressing U-2 OS cells were established and stained with 2G5 MAb. U-2 OS mock cells transfected with empty lentivirus
vector and selected with puromycin were analyzed as a control
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ruses, the 2G5 based ELISPOT assay might be fur-
ther developed to measure the neutralizing antibody
titers of serum samples.Feasibility of the ELISPOT-NT
Based on the previous findings, we next evaluated the
feasibility of ELISPOT based neutralizing test (ELI-
SPOT-NT) using 2G5 antibody on determining the
ab c
Fig. 2 Optimized detection for HSV-1. a Infection kinetics of HSV-1. The number of spots during HSV-1 infection at a MOI of 0.005 was monitored
for 108 h. The average numbers of spots were calculated from triplicate experiments, and the error bars show the standard deviations. b Spot
detection with different dilutions of 2G5 MAb. The monolayer U-2 OS cells were infected with KOS at a MOI of 1 × 104 PFU, then detected by
serially diluted 2G5 detection antibody. c Relationship between the infectious dose and the number of spots. The number of spots was obtained
from triplicate infection under a series of infectious doses ranged from 2000 PFU to 12000 PFU. An irrelevant antibody was used as a
negative control
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verify this, we first selected a NAb-positive serum sam-
ple, a NAb-negative serum sample and a negative con-
trol (PBS) for testing. As shown in Fig. 3a, it was found
that the spot counts decreased along with the increasing
folds of dilution in the NAb-positive serum, while there
was no any inhibition effect in the NAb-negative serum.
Moreover, it was necessary to investigate whether the
neutralizing antibody titers of human serum samples
can be reliably measured by use of ELISPOT-NT under
different experimental variations, such as infectious
dose. Thus, three independent serum samples were mea-
sured with the ELISPOT-NT under different infectious
doses. As shown in Fig. 3b, c and d, the results obtained
from the ELISPOT-NT were repeatable and consistent,
the infectious doses did not influence the neutralizing
antibody titers (NT50) of three independent serum sam-
ples. Due to the limit of serum usage, determining the
neutralizing antibody titer become difficult for serum
samples with NT50 below 5. Thus, if the NT50 of a
serum sample (both IgG and IgM negative) was below 5,
it would be defined as negative (unpublished data).Correlation between PRNT and ELISPOT-NT
The PRNT is the standard method for the measurement
of NAb titers against HSV-1. Therefore, we evaluated
the concordance between the PRNT and ELISPOT-NT.
22 serum samples representing different neutralizing
antibody titers were selected and tested in three inde-
pendent experiments using both PRNT and ELISPOT-
NT assay. As shown in Fig. 4a, the NAb titers of 22
serum samples measured by ELISPOT-NT were almost
equal to the those obtained from PRNT. There was a
good correlation between these two assays by linear re-
gression analysis (R2 = 0.9682) (Fig. 4b). Since the NT50
values tested by the ELISPOT-NT assay were consistent
with those tested by classical PRNT assay, it indicated
that the ELISPOT-NT had good repeatability and reli-
ability. In conclusion, the ELISPOT-NT can be used to
measure the NAb titers against HSV-1 in human serum
samples.
Characteristics of study participants
Using the ELISPOT-NT, we screened a cohort consisting




Fig. 3 Feasibility of ELISPOT-NT. a The assessment of two independent serum samples by ELISPOT-NT. Number of spots obtained from serial
dilutions of one positive serum and one negative serum was shown. For the ELISPOT-NT, the incubation time was set to 14 h and the infectious
dose was set to 1 × 104 PFU. b Influence of the infectious dose on the accuracy of ELISPOT-NT. The neutralizing antibody titers (NT50) of three
independent serum samples (designated as A, B and C) and the number of spots was measured under different infectious doses. All of the NT50
values were log2-transformed. Results represent mean ± SD from three independent experiments
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general population. This study enrolled 269 healthy indi-
viduals from Xiamen city (Table 1). Participants were aged
1–59 (mean: 30.0 ± 17.1) years and included 126 males
and 143 females. Participants were divided into five age
groups. The study samples were representative of the gen-
eral population from Xiamen, a coastal city of China.
The prevalence of NAbs against HSV-1 in general
population
The seroprevalence rate of HSV-1 infection was 79.9 %
in this cohort (215/269), which was slightly higher in
males. Due to the high seroprevalence, the prevalence of
NAbs against HSV-1 was calculated and found to be
83.6 % (225/269), with average NAb titers (log2NT50) of
8.3 ± 2.8 (Fig. 5a). Comparing the neutralizing antibody
titers against HSV-1 among different age groups, the
average NAb titers increased with the ages, a significant
difference in NAb titers was observed among groups
with age younger than 30, but there was no significant
difference among groups with age greater than 20
(Fig. 5b). No significant difference in NAb titers was ob-
served between males and females (Fig. 5c). The anti-
HSV-1 IgG level of individual was not fairly consistent
with the level of NAb titers in this cohort (R2 = 0.4165).
Interestingly, all individuals tested with HSV-1 IgG
positive were presenting with HSV-1 NAb positive,
but 10 individuals tested with HSV-1 IgG negative by
ELISA were presenting with NAb positive, possiblydue to the missed detection of HSV-1 ELISA assay
(Fig. 5d).
Discussion
Although PRNT has been accepted worldwide as the
gold standard for measuring NAb titers against viruses,
it is also known that some deficiencies of PRNT, such as
time-consuming and labor-intensive, restricts the usage
of this method in high throughput screening. Therefore,
some novel assays for titration of NAbs had been devel-
oped, such as neutralization assays based on a reporter
gene, flow cytometry and ELISPOT [22, 23]. Recently,
ELISPOT-NT have showed some advantages in assessing
the NAb titer with higher sensitivity and better concord-
ance with PRNT than other assays, which relied on the
antibodies to recognize the infected cells that express
specific viral proteins [16, 20, 21]. Usually, the viral pro-
teins selected need to be abundantly expressed during
the initial infection and be accessible by the antibodies.
The secondary antibodies coupled to horseradish perox-
idase can further improve the sensitivity of the assay by
enzyme amplification effect. To our knowledge, a feas-
ible ELISPOT-NT for detecting NAbs against herpes
virus had not been established before. Therefore, we
screened a panel of MAbs against HSV-1 to test if they
can detect the HSV-1 infected cells with high specificity
and sensitivity. We selected an antibody, named 2G5
and specifically recognized the glycoprotein D, which
could be used for detection of HSV-1 infection. Based
ab
Fig. 4 Comparison of the PRNT and ELISPOT-NT. a The neutralizing
antibody titers of 22 human serum samples, representing different
titers, were assayed by PRNT and ELISPOT-NT independently. The
average NT50 of each sample by these two tests was log2-transformed
and shown in side by side. The testing serum samples were arranged
from low titer to high titer. b The average NT50 value of each serum
sample that was assayed by the ELISPOT-NT was plotted against the
average NT50 value of corresponding serum sample that was assayed
by the PRNT. The concordance between ELISOT-NT and PRNT was
shown by linear regression analysis. Results represent mean ± SD from
three independent experiments
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able ELISPOT assay for determining the NAb titers. Fac-
tors that may impact the accuracy of this assay has been
systematically evaluated, it turns out that this assay is re-
producible and consistent within a broad linear range of
infectious doses. The theory that the neutralizing anti-
body titers are not impacted by the infectious doses is
simply the reflection of “the percentage law”, which states
that if the antibody concentration is way above the virus
concentration, a given concentration of antibody neutral-
izes the same relative proportion of virus infectivity irre-
spective of the quantity of virus present [24, 25].
Taking the results of PRNT as the reference, ELISPOT-
NT gave similar results in testing the neutralizing anti-
bodies among all representing 22 sera. A good correlation
(R2 = 0.9682; P < 0.0001) was observed between PRNT and
ELISPOT-NT. Compared with the PRNT, the ELISPOT-
NT is an efficient neutralization test with several advan-
tages: it is rapid and the whole procedure can be finished
within 24 h, from the time cells are seeded into platesuntil the data is analyzed; it is more flexible, the infectious
dose within a relatively wide range has little influence on
the results; it is precise, the titration of NAbs is repeatable
and consistent with the result obtained from PRNT; it is
high throughput, thousands of samples can be tested in a
single run. Recently, Blevins et al. reported a high
throughput assay to quantify the NAb titer against herpes
simplex viruses in human serum samples, this assay
employed a ELVIS cell line, which was stably transfected
with the LacZ gene under the control of the HSV ICP6
promoter [26]. Under the circumstance of HSV infection,
the LacZ protein was expressed and could be detected by
addition of CPRG substrate. The NAb titer could be con-
sistently quantified using this assay, but the correlation
data between this assay and classical PRNT assay was not
reported. ELISPT-NT requires less operation time than
ELVIS cell-based assay (24 h vs. 46 h). However, both
these two assays are not fully automated, require 2 ~ 3 h’s
plate manipulation.
Protection against HSV-1 infection correlates well with
the antibody levels, whereas the exact role for NAbs in
controlling HSV-1 infection and reflecting T-cell re-
sponses remains elusive [27, 28]. ELISPOT-NT shows po-
tential as a powerful method for screening neutralization
activities of large numbers of serum samples. From a co-
hort of general population with different ages in Xiamen,
we observed a significant increasing trend in the average
NAb titers along with the age, suggesting that the general
population were suffered from lifelong challenge by HSV-
1 virus. For the first time, we found that HSV-1 serologic
status was not fully related to the NAb titers, 10 individ-
uals tested with HSV-1 IgG negative by ELISA were pre-
senting with NAb positive, which implied that the
different clinical significances for anti-HSV-1 IgG level
and the neutralizing antibody titers. A reasonable explan-
ation is there are several types of neutralizing antibodies
against more than five HSV-1 proteins, but the current
HSV-1 IgG ELISA kits may only target one or two major
ones. Thus, further learning the level of NAbs response to
infection in general populations is important for under-
standing how these protective Abs may affect the HSV-1
recurrence, including their significance in the develop-
ment of vaccines against herpes virus.
Although HSV-1 harbors a high similarity with HSV-2,
the biologic characteristics of them are obviously differ-
ent. The development of a vaccine to prevent HSV-2 in-
fection had been failed due to inconsistently effective
results in people with different serologic status of herpes
virus acquired from the clinical trails [29]. Interestingly,
in women who were negative for antibodies to both
HSV-1 and HSV-2, HSV-2 gD-2 vaccine seemed to pro-
tect a small proportion of them from HSV-1 infection
rather than HSV-2 infection [3]. However, the factor
contributes to this type-specific protection remains
Table 1 Baseline characteristics of a cohort from general population in Xiamen
Group n (%) HSV-1 seroprevalence (%) HSV-1 NAb prevalence (%) Average NAb titers (log2NT50)
Age (years)
≤10 41 (15.2 %) 29.3 % (17.6 %-44.5 %)* 31.7 % (19.6 %-47.0 %)* 4.4 ± 3.1
11-20 47 (17.5 %) 74.5 % (60.5 %-84.8 %)* 74.5 % (60.5 %-84.8 %)* 7.5 ± 3.1
21-30 41 (15.2 %) 92.7 % (80.6 %-97.5 %) 95.1 % (83.9 %-98.7 %) 9.2 ± 1.6
31-40 49 (18.2 %) 91.8 % (80.8 %-96.8 %) 97.9 % (89.3 %-99.6 %) 9.1 ± 1.4
41-50 48 (17.8 %) 91.7 % (80.5 %-96.87 %) 97.9 % (89.1 %-99.6 %) 9.5 ± 1.7
>50 43 (16.0) 97.7 % (87.9 %-99.6 %) 100 % (91.8 %-100 %) 9.8 ± 1.6
Gender
Male 126 (46.8 %) 83.3 % (75.9 %-88.8 %) 84.9 % (77.7 %-90.1 %) 8.2 ± 2.8
Female 143 (53.2 %) 76.9 % (69.4 %-83.1 %) 82.5 % (75.5 %-87.9 %) 8.4 ± 2.9
Total 269 79.9 % (74.7 %-84.3 %) 83.6 % (78.8 %-87.6 %) 8.3 ± 2.8
*p < 0.05; 95 % confidence interval shown in brackets
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some differences in the antibody activity against HSV-1
and HSV-2. To prove this point, the NAb titers of
vaccine-induced antibodies against HSV-1 should be de-
termined. This setback in the development of HSV-2
vaccine provides some important information for futurea
c d
b
Fig. 5 Application of ELISPOT-NT on assessing the neutralizing antibody tit
were shown as log2 (NT50). b The average NAb titers among different age
differences between bars 1 and 2 (p < 0.005) and between bars 2 and 3 (p
no statistically significant difference was found among bars 3, 4, 5 and 6 (p
NAb titers of each sex or age group were shown in box and whiskers, whic
maximum titer levels. d Relationship between the anti-HSV IgG level and th
cohort were tested by commercial anti-HSV-1 IgG ELISA kit, the NAb titers
from this cohort were confirmed with HSV-1 IgG negative but NAbs Positivdesign of new generation vaccines, which can elicit
higher titers of NAbs than those induced by natural in-
fection, or induce stronger T cell response [8].
The HSV-1 based oncolytic virus, Talimogene laher-
parepvec, had been confirmed to be therapeutically po-
tent in a phase 3 trial of treating metastatic melanomaers against HSV-1 in a cohort. a The overall NAbs titers of this cohort
groups. This cohort was divided into five age groups as shown. The
< 0.05) were statistically significant by Mann–Whitney test. In contrast,
> 0.05). c The average NAb titers between males and females. The
h shows the minimum, first quartile, median, third quartile and
e NAb titers of 269 serum samples. The anti-HSV-1 IgG values of this
were assayed by ELISPOT-NT and were shown as log2 (NT50). 10 sera
e
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Additionally, more than 5 HSV-1 based oncolytic viruses
had also been proved to be safe and effective in the differ-
ent clinical trials against multiple cancers [32–35]. NAbs
against HSV-1 are one of the barriers viruses encounter
during viral replication in vivo [36]. However, it is largely
unknown whether the circulating NAbs in cancer patients
will restrict the efficacy of HSV-1 based oncolytic virother-
apy, especially when the viruses are administrated through
intravenous delivery [13]. A survey we conducted in the
general population by testing the NAb titers against HSV-
1 revealed that the average NAb titers were 8.3 ± 2.8, and
the prevalence of NAbs against HSV-1 increased with age,
with an older population (above 50 years old) having the
highest NAb titers (the average neutralizing antibody titers
was 9.8 ± 1.6). As we know, older adults have a higher risk
for cancer, it’s intriguing for us to know whether the NAbs
will reduce the efficacy of oncolytic virus mediated cancer
remission in patients with higher NAb titers, especially
among those with elder ages. Further studies are still
needed to design for supporting the importance of NAbs
against HSV-1 so as to broaden the application of this
ELISPOT-NT.
Conclusions
We established an HSV-1 neutralization test based on the
enzyme-linked immunospot assay (ELISPOT-NT) to de-
termine the neutralizing antibody titer against HSV-1 in
human serum samples. In this test, we employed a mono-
clonal antibody specifically recognizing glycoprotein D to
detect the cells that were infected with HSV-1. Using this
high-throughput test, the neutralizing antibody titers
against HSV-1 from human sera can be detected precisely
within 24 h. The stability and consistency of this assay was
systematically evaluated in parallel with a conventional
neutralization test, a good correlation in determining the
neutralizing antibody titers was observed. Through a co-
hort study, in the general population consisting of 269
healthy individuals in Xiamen City of China, we observed
significant differences in neutralizing antibody titers across
the different ages by using this test. We also demonstrated
that the anti-HSV-1 IgG level was not closely associated
with neutralizing antibody titers. The ELISPOT-NT test
could serve as an accurate and simple assay for large
cohort studies in assessing the role of the neutralizing
antibody titers against HSV-1 on the development of




Human U-2 OS cells and HEK 293 T cells were pur-
chased from American Type Culture Collection (ATCC)
and maintained in Dulbecco’s modified Eagle’s medium(DMEM) containing 10 % fetal bovine serum (FBS), 100
U/mL penicillin, and 100 μg/mL streptomycin. U-2OS
cells are widely recognized as a common cell model for
HSV-1 titration and functional study of HSV-1 infection
[37–39]. Besides, U2OS cells are a good cell option for
spot detection due to their characteristics of big size and
round shape. Herpes simplex virus 1, KOS strain, was
purchased from ATCC. Viruses were propagated and ti-
trated in U-2 OS cells, and kept in storage at −80 °C.
Plasmids and transfection
Lentivirus vector was purchased from Addgene. The
HSV-1 glycoprotein genes (gB ~ gN) were amplified
from KOS genome and subcloned into lentivirus vector.
Lentivirus constructs with glycoprotein-expressing genes
(plv-gB ~ gN) were co-transfected respectively in 293 T
cells along with helper vectors using Lipofectamine 2000
according to the manufacturer’s instructions (Invitrogen).
For viral transduction, the U-2 OS cells were transduced
with the medium containing lentivirus harvested 48 h after
transfection, in the presence of 6 μg/mL polybrene. Stable
clones were selected under the pressure of puromycin.
Human serum samples
Serum samples from 269 healthy individuals with vari-
ous ages were collected at random times throughout
2014 from the Center for the Disease Control and Pre-
vention (CDC) of Xiamen. All study participants resided
in the city of Xiamen.
ELISA
Total antibodies against HSV-1 in this cohort was deter-
mined by HSV-1 IgG ELISA kit (Wantai Bio). Tests were
performed as described in the manufacturer’s instruction
manuals. In brief, 100 μl of a 5-fold diluted serum sam-
ple was added to the microplate well and incubated at
37 °C for 1 h. After stringent washing, and then 100 μl
of HRP-conjugated secondary antibody was added and
incubated 37 °C for 0.5 h. The wells were washed three
times, 100 μl of TMB substrate was added and incubated
15 min at room temperature. Subsequently, 50 μl of stop
solution was added and the absorbance value (expressed
as optical density [OD]) was read by an ELISA plate
reader. The result of tests were defined as follows: OD
values > 0.1, positive; OD values ≤0.1, negative, the tests
would be repeated by using 100 μl serum samples.
Antibody production
For the preparation of anti-HSV-1 monoclonal anti-
bodies, six-week-old female BALB/c mice were immu-
nized with KOS viruses by standard prime and boost
vaccination procedure. The hybridoma cells were ob-
tained following the protocol reported previously [40].
The positive clones were screened and selected by
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staining assay that the antibodies can specifically bind to
the HSV-1 infected cells. MAbs were prepared by ascites
production and purified by using protein G chromatog-
raphy according to the manufacturer’s instructions.
ELISPOT
U-2 OS cells were seeded in 96-well plates at a density
of 2 × 104 cells per well and incubated for 6 h at 37 °C in
5 % CO2 until the cells became monolayer. 1 × 10
4 PFU
viruses in a volume of 100 μL were added to the mono-
layer cells and incubated for 14 h. After infection, the
cells were fixed with 1 % paraformaldehyde in PBS for
5 min and followed by permeabilization with 0.1 %
Triton X-100 in PBS at room temperature for 5 min. Next,
each diluted monoclonal antibody (10 μg/mL) was added
and incubated at 37 °C for 1 h. After reaction with the
HRP-conjugated secondary antibody (1:2000), the spots
were developed in TMB substrates (Sigma) within 15 min.
Last, the plates were spin dried and counted using
ImmunSpot@S5 UV Analyzer (Cellular Technology
Limited). Each antibody was repeated in triplicate wells
and each test was carried out in duplicate or triplicate. An
irrelevant antibody, which specifically recognized HBV
envelope protein, was used as a negative control.
Western Blotting
Western blotting was done as previously described [41].
In brief, cells were lysed in lysis buffer (20 mM Hepes,
1 mM EGTA, 5 mM MgCl2, 100 mM NaCl, 4 mg/mL
Decyl-beta-D-maltopyranoside, 10 % glycerol and prote-
ase inhibitor cocktail). Cell lysates were separated by
SDS-PAGE and transferred onto a nitrocellulose mem-
brane. After membranes were blocked with 5 % BSA for
1 h, they were probed with indicated primary antibodies
(8 μg/mL) overnight at 4 °C, followed by incubation with
the HRP-conjugated secondary antibodies for 1 h at
room temperature, and finally visualized with the Lumi-
LightPLUS Western blotting Substrate (Roche).
Immunofluorescence
Standard immunofluorescence staining was performed
as previously described [40]. In brief, cells on the glass
slides were fixed with 1 % paraformaldehyde and perme-
abilized by 0.1 % Triton X-100. After blocked with 5 %
normal goat serum in PBS for 1 h, the slides were
stained with primary antibody 2G5 (8 μg/mL) overnight
at 4 °C, then incubated with FITC conjugated secondary
antibody before examination using confocal microscope.
Plaque reduction neutralization test
U-2 OS cells were seeded in 6 cm dishes at a density of
1 × 106 cells per well and cultured for 2 days at 37 °C in
5 % CO2 until the cells became monolayer. All serumsamples were heat inactivated at 56 °C for 30 min prior
to testing. The test serum samples were first diluted 20-
fold in DMEM containing 10 % heat inactivated FBS,
followed by two-fold serial dilutions from 1:40 to
1:10240. An equal volume of viral dilution, containing
100 PFU viruses, was mixed with the diluted serum and
incubated at 37 °C in 5 % CO2 for 1 h. Then the total
mixture in a volume of 0.5 mL per dish was added
evenly to the U-2 OS cells and incubated for 1.25 h.
During the incubation, the infected dishes were shaken
gently every 15 min. After the initial infection, the inoc-
ulums were removed and 4 mL fresh culture medium
were added to facilitate the viral entry. After another 2 h
incubation, the cell monolayers were overlaid with
10 mL of 2 % methylcellulose medium and then incu-
bated at 37 °C in 5 % CO2 for 3 days. Last, the dishes
were stained with 5 mL of 0.01 % neutral red for over-
night, then the plaques were counted by use of a white-
light transilluminator manually. Virus control wells were
infected with the same amount of virus as the testing
wells mixed with serially diluted serum. Each serum di-
lution was repeated in triplicate wells and each test was
carried out in duplicate or triplicate. The raw data of
each sample by PRNT method was calculated in a for-
mula as follows: % reduction = 100 × [1-(average plaque
counts for each dilution/average plaque counts for virus
control) [16]. If the % reduction were below 50 %, the
serum samples were retested by starting a dilution from
5-fold.
ELISPOT based neutralization test
U-2 OS cells were seeded in 96-well plates at a density
of 2 × 104 cells per well and incubated for 6 h at 37 °C in
5 % CO2 until the cells became monolayer. Serial dilu-
tions of serum samples were prepared as described for
PRNT with minor modifications. 1 × 104 PFU viruses in
a volume of 50 μL were mixed with an equal volume of
serial diluted serum samples and incubated at 37 °C in
5 % CO2 for 1 h in 96-well plates with U bottom shape.
Then the mixture was added to the monolayer cells and
incubated for 14 h. The optimal infectious dose and in-
cubation time were determined in preliminary experi-
ments in order to acquire reliable spot counts. Then,
standard ELISPOT procedure was performed as previ-
ously described. Each serum dilution was repeated in
triplicate wells and each test was carried out in duplicate
or triplicate. The reduction rate of the serum sample can
be calculated in the same manner as for PRNT.
Data analysis
The 50 % inhibitory concentration (IC50) of each sample
is defined as the highest dilution that gave 50 % plaque
reduction. The neutralizing antibody titers can be inter-
preted as the highest serum dilution that neutralizes
Luo et al. Virology Journal  (2016) 13:44 Page 10 of 1150 % of the viruses (NT50), which was calculated by non-
linear, dose–response regression analysis using Graphpad
Prism software. The correlation between the two methods
was analyzed by linear regression using SPSS 16.0 soft-
ware. The average NAb titers across different ages were
compared using two-tailed Mann–Whitney U test. A
P value of less than 0.05 was considered statistically
significant, and the confidence interval (CI) was 95 %.
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